Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer

Until 2020, the standard treatment for rectal cancer was a combination of radiotherapy and concomitant chemotherapy based on IV or oral 5FU, with a low complete response rate. The randomised phase 3 PRODIGE 23 trial evaluated a regimen of FOLFIRINOX chemotherapy prior to neoadjuvant RTCT, with 3-year disease-free survival as the primary endpoint. Patients in the PRODIGE 23 arm had significantly better 3-year disease-free survival (76% versus 69%; p=0.034) and 3-year metastasis-free survival (79% versus 72%; p=0.017) than patients in the standard arm, and the complete histological response rat

Trial Details

NCT ID
NCT06536127
Phase
NA
Sponsor
Institut Sainte Catherine
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Blood samples
Locations (sample)
  • Avignon, France|43.94834,4.80892

Key Eligibility Criteria

  • Age ≥ 18 years
  • Histologically proven adenocarcinoma of the rectum
  • Patient with rectal cancer (cT2-4N0 or cT1-T4N+)
  • Patients whose planned treatment is: standardised CTRT comprising 50Gy intensity-modulated irradiation and Capecitabine with or without additional …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →